IRIS International Inc. says it is collecting clinical data for its NADiA ProsVue prostate cancer molecular diagnostic with hopes of gaining Medicare reimbursement in 2013.
Iris International Seeks Reimbursement For Its Prostate Molecular Dx
The firm, soon to be acquired by Danaher, is pursuing a major data collection effort to gain reimbursement for its ultrasensitive prostate cancer assay, following a 300-patient trial to support 510(k) clearance.